Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease

van Heel, D A, Ghosh, S, Hunt, K A, Mathew, C G, Forbes, A ORCID: https://orcid.org/0000-0001-7416-9843, Jewell, D P and Playford, R J (2005) Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease. Gut, 54 (11). pp. 1553-7. ISSN 0017-5749

Full text not available from this repository. (Request a copy)

Abstract

Nucleotide binding oligomerisation domain 2 (NOD2; also known as CARD15) mutations are associated with Crohn's disease but how mutations cause disease is poorly understood. Innate immune responses are reportedly enhanced by combined NOD2 ligand (muramyl dipeptide, MDP) and Toll-like receptor 4 ligand (TLR4, lipopolysaccharide) stimulation. Intestinal TLR signalling has a dual role-maintaining intestinal homeostasis and protection from injury as well as initiating inflammatory responses. TLR9 is functional in the intestinal epithelium where it is most strongly expressed in Paneth cells.

Item Type: Article
Uncontrolled Keywords: acetylmuramyl-alanyl-isoglutamine,adult,blotting, western,cells, cultured,cpg islands,crohn disease,drug synergism,enzyme-linked immunosorbent assay,female,humans,immunity, mucosal,interleukin-8,intestinal mucosa,intracellular signaling peptides and proteins,ligands,male,membrane glycoproteins,middle aged,mutation,nod2 signaling adaptor protein,receptors, cell surface,reverse transcriptase polymerase chain reaction,toll-like receptor 4,toll-like receptor 9,toll-like receptors,tumor necrosis factor-alpha
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology
Faculty of Medicine and Health Sciences > Research Groups > Nutrition and Preventive Medicine
Depositing User: Pure Connector
Date Deposited: 06 Aug 2014 10:58
Last Modified: 20 Oct 2022 23:59
URI: https://ueaeprints.uea.ac.uk/id/eprint/49638
DOI: 10.1136/gut.2005.065888

Actions (login required)

View Item View Item